INZY   $5.95  2.50% Market Open

Inozyme Pharma Inc
Last Events:

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in Stochastic changed from bearish recovery to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: main and signal line crossing.

2023-08-05 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: main and signal line crossing.

2023-08-05 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-03 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it grows. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-03 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-02 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-07-30 Trend pattern changed from канал to расширяющаяся формация.


Current temperature: 10.84
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 8
Target Price Mean 19.00
Mean unverified/preliminary 19.00 / 19.00
Target Price Low / High 13.00 / 40.00
Median / STD DEV 15.50 / 9.04
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi ActivelyBuy None ActivelyBuy
macd None None None
stoch Sell None None
ma20 ActivelyBuy ActivelyBuy None
ma50 None None None
ma100 Buy ActivelyBuy ActivelyBuy
Candlestick PatternSept. 18, 2024 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US45790W1080
ceo Dr. Douglas A. Treco Ph.D.
Website https://www.inozyme.com
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.